Gene therapy (AAV vector) · Gene silencing: superoxide dismutase 1 (SOD1) · developed by UniQure Biopharma B.V.
AMT-162 is a nonreplicating, self-complementary recombinant adeno-associated virus vector based on serotype rh10 that carries cDNA encoding an artificial microRNA targeting SOD1. It is being studied in amyotrophic lateral sclerosis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06100276 | Phase 1/2 | Amyotrophic Lateral Sclerosis | Active not recruiting | QURE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Amyotrophic Lateral Sclerosis
Updated Oct 25, 2026. Something wrong or missing? Report it on the QURE page.
See QURE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
QURE catalysts and pipeline →